Skip to main content
SpringerLink
Log in

Cytokines with Possible Clinical Utility

  • Conference paper
Modern Trends in Human Leukemia VII

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 31))

  • 36 Accesses

Abstract

Biological response modifiers (BRM) are agents aimed at reducing tumor growth, not primarily by exerting direct cytotoxic effects but by modulation of tumor gene expression (e.g., induction of differentiation) or by enhancing host defense mechanisms directed against cancer cells. BRM as primary therapy or as adjuncts to cytotoxic agents in the treatment of cancers have attracted increasing interest in view of stagnating clinical results in many areas [1], and there is increasing evidence of in vitro and in vivo efficacy of these agents. Furthermore, advances in molecular biology suggesting that oncogenes and their products play a crucial role in oncogenesis support approaches to modulation of regulatory mechanisms as a means of controlling tumor cell growth.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bailar JC, Smith EM (1986) Progress against cancer? N Engl J Med 314:1226–1232

    Article  PubMed  Google Scholar 

  2. Herrmann F, Cannistra SA, Griffin JD (1986) T cell-monocyte interactions in the production of humoral factors regulating human granulopoiesis in vitro. J Immunol 136:2856–2862

    PubMed  CAS  Google Scholar 

  3. Morgan DA, Ruscetti FW, Gallo RC (1976) Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 193:1007–1008

    Article  PubMed  CAS  Google Scholar 

  4. Gillis S, Smith KA (1977) Long-term culture of tumor-specific cytotoxic T cells. Nature 268:154–156

    Article  PubMed  CAS  Google Scholar 

  5. Gillis S, Baker PE, Ruscetti FW, et al. (1978) A long-term culture of human antigen-specific cytotoxic T cell lines. J Exp Med 148:1093–1098

    Article  PubMed  CAS  Google Scholar 

  6. Flomenberg N, Weite K, Mertelsmann R, et al. (1983) Interleukin 2-dependent natural killer (NK) cell lines from patients with primary T cell immunodeficiencies. J Immunol 130:2635–2643

    PubMed  CAS  Google Scholar 

  7. Henney CS, Kuribayashi K, Kern DE, et al. (1981) Interleukin 2 augments natural killer cell activity. Nature 291:335–338

    Article  PubMed  CAS  Google Scholar 

  8. Trinchieri G, Matsumoto-Kobayshi M, Clark SC, et al. (1984) Response of resting peripheral blood natural killer cells to interleukin 2. J Exp Med 160:1147–1169

    Article  PubMed  CAS  Google Scholar 

  9. Grimm EA, Mazumder A, Zhang HZ, et al. (1982) Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2 activated autologous peripheral blood lymphocytes. J Exp Med 155:1823–1841

    Article  PubMed  CAS  Google Scholar 

  10. Howard M, Matis L, Malck TR, et al. (1983) Interleukin 2 induces antigen-reactive T cell Unes to secrete BCGF-1. J Exp Med 158:2024–2039

    Article  PubMed  CAS  Google Scholar 

  11. Kasahara T, Hooks JJ, Dougherty SF, et al. (1983) Interleukin 2 mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol 130:1789–1989

    Google Scholar 

  12. Pearlstein KT, Palladino MA, Weite K, et al. (1983) Purified human interleukin 2 enhanced induction of immune interferon. Cell Immunol 80:1–9

    Article  PubMed  CAS  Google Scholar 

  13. Zubler RH, Lowenthal JW, Erard F, et al. (1984) Activated cells express receptor for, and proliferate in response to, pure interleukin 2. J Exp Med 160:1170–1183

    Article  PubMed  CAS  Google Scholar 

  14. Waldmann TA, Goldman CK, Robb RJ, et al. (1984) Expression of interleukin 2 receptors on activated human cells. J Exp Med 160:1450–1466

    Article  PubMed  CAS  Google Scholar 

  15. Boyd AW, Fisher DC, Fox DA, et al. (1985) Structural and functional characterization of IL-2 receptors on activated human cells. J Immunol 134:2387–2392

    PubMed  CAS  Google Scholar 

  16. Ralph P, Jeong G, Weite K, et al. (1984) Stimulation of immunoglobulin secretion in human B-lymphocytes as a direct effect of high concentrations of IL-2. J Immunol 133:2442–2445

    PubMed  CAS  Google Scholar 

  17. Herrmann F, Cannistra SA, Levine H, et al. (1985) Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med 162:1111–1116

    Article  PubMed  CAS  Google Scholar 

  18. Kruger G, Weite K, Ciobanu N, et al. (1984) Interleukin 2 correction of defective in vitro T cell mitogenesis in patients with common variable immunodeficiency. J Clin Immunol 4:295–303

    Article  PubMed  CAS  Google Scholar 

  19. Ciobanu N, Weite K, Kruger G, et al. (1983) Defective T cell response to PHA and mitogenic monoclonal antibodies in male homosexual with acquired immunodeficiency syndrome and its in vitro correction by interleukin 2. J Clin Immunol 3:332–340

    Article  PubMed  CAS  Google Scholar 

  20. Murray HW, Weite K, Jacobs JL, et al. (1985) Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome. J Clin Invest 76:1959–1964

    Article  PubMed  CAS  Google Scholar 

  21. Weite K, Ciobanu N, Moore MAS, et al. (1984) Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T-lymphocyte proliferation by highly purified interleukin 2. Blood 64:380–385

    Google Scholar 

  22. Antonacci A, Calvano SE, Reaves A, et al. (1984) Autologous and allogeneic mixed lymphocyte responses following thermal injury in man: the immunomodulatory effects of interleukin 1, interleukin 2 and a prostaglandin inhibitor, WY-18251. Clin Immunol Immunopath 30:304–320

    Article  CAS  Google Scholar 

  23. Kröncke M, Leonard WJ, Depper JM (1984) Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 81:5214–5218

    Article  Google Scholar 

  24. Arya SK, Wong-Staal F, Gallo RC, et al. (1984) Dexamethasone-mediated inhibition of human T-cell growth factor and gamma-interferon messenger RNA. J Immunol 133:273–276

    PubMed  CAS  Google Scholar 

  25. Holbrook NJ, Smith KA, Fornace AJ Jr, et al. (1984) T-cell growth factor: complete nucleotide sequence and organization of the gene in normal and malignant cells. Proc Natl Acad Sci USA 81:1634–1638

    Article  PubMed  CAS  Google Scholar 

  26. Siegal LJ, Harper ME, Wong-Staal F, et al. (1984) Gene for feline chromosome B1. Science 223:175–178

    Article  Google Scholar 

  27. Sykora KW, Kolitz J, Szabo P, et al. (1984) The human IL2 gene is located on chromosome 4. Cancer Invest 2:261–265

    Article  PubMed  CAS  Google Scholar 

  28. Cheever MA, Greenberg PD, Fefer A (1982) Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T-lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 155:968–980

    Article  PubMed  CAS  Google Scholar 

  29. Mazumder A, Rosenberg SA (1984) Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 159:495–507

    Article  PubMed  CAS  Google Scholar 

  30. Ettinghausen SE, Lipford EH, Mule JJ, et al. (1985) Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol 135:3623–3635

    PubMed  CAS  Google Scholar 

  31. Rosenberg SA, Mule JJ, Spiess PJ, et al. (1985) Regression of established pulmonary métastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161:1169–1188

    Article  PubMed  CAS  Google Scholar 

  32. Lotze MT, Frana LW, Sharrow SO, et al. (1985) In vivo administration of purified human interleukin 2. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 134:157–166

    PubMed  CAS  Google Scholar 

  33. Mertelsmann R, Weite K, Sternber C, et al. (1984) Treatment of immunodeficiency with interleukin 2: initial exploration. Resp Modif 4:483–490

    Google Scholar 

  34. Weite K, Wang CY, Mertelsmann R, et al. (1982) Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med 156:454–464

    Article  Google Scholar 

  35. Kolitz JE, Holloway K, Weite K, et al. (1985) A multiple-dose phase-I trial of recombinant interleukin 2 in advanced malignancy. Proc Am Soc Clin Oncol 135:2865–2875

    Google Scholar 

  36. Lotze MT, Frana LW, Sharrow SO, et al. (1985) In vivo administration of purified human interleukin 2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant interleukin 2. J Immunol 135:2865–2875

    PubMed  CAS  Google Scholar 

  37. Rosenberg SA, Lotze MT, Muul LM, et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and Interleukin-2 or high-dose Interleukin-2 alone. N Engl J Med 316:889–897

    Article  PubMed  CAS  Google Scholar 

  38. Houghton AN, Mintzer D, Cordon-Cardo C (1985) Mouse monoclonal IgG 3 antibody-detecting GD3 ganglioside: a phase-I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242–1246

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, University of Mainz, Mainz, Federal Republic of Germany

    R. Mertelsmann & F. Herrmann

  2. Laboratory of Cytokine Biology, Sloan-Kettering Institute, New York, NY, USA

    J. Kolitz & K. Welte

Authors
  1. R. Mertelsmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Kolitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Welte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Klinik, Abteilung für klinische Chemie, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, 2000, Hamburg 20, Germany

    Rolf Neth

  2. Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD, 20205, USA

    Robert C. Gallo

  3. Institute of Cancer Research, Chester Beatty Laboratories, Leukemia Research Fund Centre, Fulham Road, London, SW3 6JB, UK

    Melvyn F. Greaves

  4. Abteilung für Hämatologie und Onkologie, Universitäts-Kinderklinik, Martinistraße 52, 2000, Hamburg 20, Germany

    Hartmut Kabisch

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Mertelsmann, R., Kolitz, J., Welte, K., Herrmann, F. (1987). Cytokines with Possible Clinical Utility. In: Neth, R., Gallo, R.C., Greaves, M.F., Kabisch, H. (eds) Modern Trends in Human Leukemia VII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 31. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72624-8_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72624-8_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-17754-8

  • Online ISBN: 978-3-642-72624-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation